

# MAGLUMI® SARS-CoV-2 Neutralizing Antibody (CLIA) CE Marked!

Addressing the urgent need of assessing immunity during the COVID-19 pandemic

The fully automatic quantitative determination of MAGLUMI® SARS-CoV-2 Neutralizing Antibody Assay specializes in:

- An important tool of the COVID-19 vaccine efficacy assessment.
- Evaluating immunity in individuals and community to provide immunity “certification” for returning to society.
- Cost-effective and large-scale solution for neutralizing antibody test.
- Highly sensitive and specific detection of neutralizing antibodies: 100% positive agreement\* to gold standard Virus Neutralization Test (VNT) ensures accurate results.



Clinical platform base with  
**15000**  
analyzers worldwide




First result available within  
**20 mins<sup>^</sup>**




High throughput of  
**14400 tests/day<sup>^</sup>**

## MAGLUMI® SARS-CoV-2 Neutralizing Antibody Detection



Same Kit for MAGLUMI® Multi-Size Automated Analyzers  
Analyzers can be connected with Major Lab Automation ( / )



<sup>^</sup> Depending on samples and Assays configuration on MAGLUMI® X8 analyzer.  
\* According to study in MAGLUMI® SARS-CoV-2 Neutralizing Antibody IFU.